ARCA biopharma, Inc.

NasdaqCM:ABIO Stock Report

Market Cap: US$50.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

ARCA biopharma Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Tom Keuer

Chief executive officer

US$400.8k

Total compensation

CEO salary percentage84.8%
CEO tenure9.7yrs
CEO ownership0.3%
Management average tenureno data
Board average tenure7.5yrs

Recent management updates

Recent updates

Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Apr 04
Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Sep 24
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

May 03

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Mar 18
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Nov 27
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Jul 15
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Mar 30
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19

Dec 15

We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

Dec 15
We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth

ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment

Nov 24

ARCA biopharma reports Q3 results

Nov 02

CEO Compensation Analysis

How has Tom Keuer's remuneration changed compared to ARCA biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$401kUS$340k

-US$5m

Sep 30 2023n/an/a

-US$5m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023n/an/a

-US$8m

Dec 31 2022US$449kUS$340k

-US$10m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$421kUS$339k

-US$19m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$16m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$631kUS$285k

-US$10m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020n/an/a

-US$5m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$304kUS$283k

-US$5m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$6m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018US$327kUS$303k

-US$8m

Sep 30 2018n/an/a

-US$11m

Jun 30 2018n/an/a

-US$13m

Mar 31 2018n/an/a

-US$17m

Dec 31 2017US$457kUS$302k

-US$18m

Compensation vs Market: Tom's total compensation ($USD400.80K) is below average for companies of similar size in the US market ($USD680.27K).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.

CEO

Tom Keuer (65 yo)

9.7yrs

Tenure

US$400,802

Compensation

Mr. Thomas A. Keuer, also known as Tom, serves as President & Principal Executive Officer of ARCA Biopharma, Inc. since April 3, 2024 and has been the Chief Operating Officer since December 1, 2014. Mr. Ke...

Board Members

NamePositionTenureCompensationOwnership
Linda Grais
Independent Director17.3yrsUS$162.50k0%
$ 0
Anders Hove
Independent Director7.5yrsUS$150.00k0%
$ 0
Robert Conway
Independent Chairman of the Board10.9yrsUS$195.00k0.34%
$ 174.5k
Jacob Ma-Weaver
Director2.2yrsUS$130.00kno data
James Flynn
Independent Director1.7yrsUS$40.00k0%
$ 0

7.5yrs

Average Tenure

58yo

Average Age

Experienced Board: ABIO's board of directors are considered experienced (7.5 years average tenure).